Home /
Chemotherapy – The University of Texas M.D. Anderson Cancer Center
|
|
| Description: |
| Patients: This Phase II study involved 24 patients with malignant pleural mesothelioma
Treatment: The treatment consisted of the administration of the drug Doxil. Toxicity: Toxicities included cardiac, mild elevations of alkaline phosphatase, nausea, and hematological. One patient had a grade 4 neutropenia. Results: No objective responses were observed and the overall median survival was 37 weeks (8.5 months). Support: The study was supported in part by Sequus Pharmaceuticals, Inc. Sequus manufactures Doxil. Correspondence: Dong M. Shin, MD |
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."